Andrew Barleben (@AndrewBarleben) header
Andrew Barleben (@AndrewBarleben) profile picture

Associate Professor Vascular and Endovascular Surgery UCSD, opinions are my own.

San Diego, CA
Joined January 2019
Photo by Andrew Barleben (@AndrewBarleben)Photo by Andrew Barleben (@AndrewBarleben)Photo by Andrew Barleben (@AndrewBarleben)Photo by Andrew Barleben (@AndrewBarleben)Photo by Andrew Barleben (@AndrewBarleben)Photo by Andrew Barleben (@AndrewBarleben)Photo by Andrew Barleben (@AndrewBarleben)Photo by Andrew Barleben (@AndrewBarleben)Photo by Andrew Barleben (@AndrewBarleben)Photo by Andrew Barleben (@AndrewBarleben)
Successful repair of rupture #pararenal #aaa for failed #EVAR with @WLGore @WLGoreMedical #TAMBE transfemoral due to frozen shoulder and shaggy arch @UCSDsurgery
3
2
1
34
2,388
Never leave a hypo or SGA behind. #evar #hypopres #IBDforall
2
2
15
611
Andrew Barleben retweeted
Ingenuity in the Cath Lab. Endovascular Aortic Root Repair (Endo-Bentall) for Acute Type A Dissection. ahajournals.org/doi/abs/10.1… @Toursavadkohi @dr_ghoreishi #TAVR #TEVAR #Cardiotwitter #AHAJournals
1
24
50
8,130
Andrew Barleben retweeted
TODAY and everyday – at Houston, TX
3
2
9
664
Andrew Barleben retweeted
So honored to have worked on this issue with such an amazing and inspiring team 🥰🥳
No better way to kick off #WomenInMedicine month than by announcing that the @avsgjournal #OriginalWorkbyWomen issue is live. 38 articles with women first and last authors🤩. Huge shoutout to the all-women editor team who curated this special issue 👏! annalsofvascularsurgery.com/…
3
12
1,886
Andrew Barleben retweeted
UPDATE: Risk of Mortality Associated with Paclitaxel-Coated Devices to Treat Peripheral Arterial Disease is No Longer Supported Based on Data and Analyses - Letter to Health Care Providers fda.gov/medical-devices/lett…
10
32
3,317
📢Have you registered for the 2023 UCSF Vascular Symposium yet? Visit our website to register and view the fast-paced program including debates, interactive case discussions, and expert panels with an outstanding multi-disciplinary faculty. vascularsymposium.ucsf.edu/
1
8
2
10
5,419
Fresh off the press. Our #HOPE team was invited to put together a step by step review of arterialization techniques. Open and endo are complimentary and each have their place. Read and share 🙏 doi.org/10.1016/j.jvscit.202… @JillSommerset @mattsmeds @hendolat @Vascupedia_com – at Houston, TX
4
11
4
46
9,716
The Cook ZFEN+ IDE is approved by the FDA to start trial. Finally a tailored, patient specific fenestrated stent-graft to repair complex aortic aneurysms with more sealing, less compromise on vessel incorporation. It will expand indications of EVAR significantly! – at Houston, TX
4
51
1
211
15,806
Andrew Barleben retweeted
Replying to @VascularHaurani
@VascularHaurani @drseanlyden and PAC leaders Mark Mattos and @phcvascular - good policy and sustainable payment are critical to vascular surgeons and the @VascularSVS mission
Degradation of the safety net, increasing consolidation, rising inflationary costs, labor shortages… there IS MORE YOU CAN DO! #getinvolved #advocacy #VAM2023 @VascularSVS members YOU can make a difference vascular.org/advocacy
3
8
1,326
Andrew Barleben retweeted
Simultaneous #VAM23 presentation and @JVascSurg publication. What a great value add for @VascularSVS members and investigators.
1
4
19
1,340
Andrew Barleben retweeted
To everyone who will be at #VAM23 if you treat TBAD and have an opinion, idea, input, criticism, concern, question or just for “the love of the game”…join us next Friday 🙏 @KougiasP @ShereneShalhub @VascularSVS @MichaelSConteMD – at Houston, TX
7
2
28
4,959
Andrew Barleben retweeted
70 years ago (May 6, 1953), Dr. John Gibbon used a heart-lung machine for the first time on an 18-year-old female ASD patient. A well-prepared giant achievement and the very begin of modern cardiac surgery! It also may remind us to foster innovation and allow disruptive ideas.
4
42
6
119
22,437
Congratulations and great work to Rohini Patel and @fallentineMS4 (who won’t be an MS4 forever) on their great presentations! Representing @UCSDsurgery at @VascularSocal!!! #scvss #scvss2023
1
1
9
511
Fresh from #asa23 in Toronto #FBEVAR in 2,603 #TAAA patients with mortality of 4.5% for elective and 17% for non-elective procedures. Risk of aortic death 9% in 5yrs. Next steps: how to reduce reintervention and cost? – at Toronto, Ontario
2
12
1
68
5,125